OncRef

Clinical Trial: NCT04545762

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:C. Babis Andreadis
Information Provided By:University of California, San Francisco
Last Update Posted:2026-10-26

Study Overview

Brief Summary

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

Official Title

A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Conditions

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma

Intervention / Treatment

  • Drug: Fludarabine
  • Drug: Cyclophosphamide
  • Biological: anti-CD19 CAR-T cells

Other Study ID Numbers

  • 19703
  • NCI-2020-06711

Start Date (Actual)

2020-09-11

Primary Completion Date (Estimated)

2026-10-31

Study Completion Date (Estimated)

2026-10-31

Enrollment (Estimated)

36

Study Type

Interventional

Phase

Phase 1